echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > The Oncologist: Treatment model and prognosis of different HER2 status in Chinese gastric cancer patients: a non-intervention registration study (EVIDENCE)

    The Oncologist: Treatment model and prognosis of different HER2 status in Chinese gastric cancer patients: a non-intervention registration study (EVIDENCE)

    • Last Update: 2021-08-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Gastric cancer (GC) is the third most common cause of cancer-related death in the world and the third most common cause of cancer-related death in China


    Gastric cancer (GC) is the third most common cause of cancer-related death in the world and the third most common cause of cancer-related death in China


    The EVIDENCE study is a prospective, multi-center, non-interventional registration study that evaluates the safety and efficacy of trastuzumab in 5 cohorts of gastric cancer patients in China, divided according to HER2 status and trastuzumab treatment Layer


    The EVIDENCE study is a prospective, multi-center, non-interventional registration study that evaluates the safety and efficacy of trastuzumab in 5 cohorts of gastric cancer patients in China, divided according to HER2 status and trastuzumab treatment Layer


    OS1 is defined as the time from the first diagnosis of recurrence or metastasis to death from any cause; first-line OS2 is defined as the time from trastuzumab treatment to death from any cause; second-line or third-line OS2 is defined as the first-line or second-line progression to death from any cause Time


    Cohorts I, II, and IV included 174, 113, and 422 patients, respectively


    In cohorts I, II, and IV, the median overall survival (OS1) of first-line treatment was 22.



    OS

    The first-line progression-free survival (PFS1) of cohorts I, II, and IV were 8.


    The first-line progression-free survival (PFS1) of cohorts I, II, and IV were 8.



    PFS

    The first-line response rate (RR) of cohort I, II, and IV were 51.


    The first-line response rate (RR) of cohort I, II, and IV were 51.



    RR

    In the first-line median OS1 (hazard ratio [HR], 0.


    In the first-line median OS1 (hazard ratio [HR], 0.


    Trastuzumab-related adverse reactions, grade 3-5 adverse reactions, serious adverse reactions, and death-causing adverse reactions accounted for 23.
    6%, 3.
    4%, 2.
    3%, and 0.
    6% of cohort I patients, respectively
    .

    In summary, the safety is consistent with the known safety of trastuzumab and chemotherapy; trastuzumab treatment improves the prognosis of patients
    .
    This study provides real-world data on first-line trastuzumab combined with chemotherapy in the treatment of HER2-positive mGC patients in China
    .

    In summary, the safety is consistent with the known safety of trastuzumab and chemotherapy; trastuzumab treatment improves the prognosis of patients
    .
    This study provides real-world data on first-line trastuzumab combined with chemotherapy in the treatment of HER2-positive mGC patients in China
    .
    The safety is consistent with the known safety of trastuzumab and chemotherapy; trastuzumab treatment improves the prognosis of patients
    .
    This study provides real-world data on first-line trastuzumab combined with chemotherapy in the treatment of HER2-positive mGC patients in China
    .
    The safety is consistent with the known safety of trastuzumab and chemotherapy; trastuzumab treatment improves the prognosis of patients
    .
    This study provides real-world data on first-line trastuzumab combined with chemotherapy in the treatment of HER2-positive mGC patients in China
    .

    Original source:

    Original source:

    S HUKUI Q IN, J IAFU JI, R UI -H UA XU, et al.
    Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).
    The Oncologist 2021;26:1–14 HUKUI Q IN, J IAFU JI, R UI -H UA XU, et al.
    Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).
    The Oncologist 2021;26:1–14

    Leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.